Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin

Nicholas J. Short; Guillaume Richard-Carpentier; Rashmi Kanagal-Shamanna; Keyur P. Patel; Marina Konopleva; Ioannis Papageorgiou; Naveen Pemmaraju; Gautam Borthakur; Farhad Ravandi; Courtney D. DiNardo; Tapan M. Kadia; Hagop Kantarjian; Jatinder K. Lamba; Naval Daver

doi:10.1002/ajh.25854

Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin

Nicholas J. Short, Guillaume Richard-Carpentier, Rashmi Kanagal-Shamanna, Keyur P. Patel, Marina Konopleva, Ioannis Papageorgiou, Naveen Pemmaraju, Gautam Borthakur, Farhad Ravandi, Courtney D. DiNardo, Tapan M. Kadia, Hagop Kantarjian, Jatinder K. Lamba, Naval Daver

Research output: Contribution to journal › Letter › peer-review

9 Scopus citations

Original language	English (US)
Pages (from-to)	E225-E228
Journal	American journal of hematology
Volume	95
Issue number	9
DOIs	https://doi.org/10.1002/ajh.25854
State	Published - Sep 1 2020

ASJC Scopus subject areas

Hematology

Access to Document

10.1002/ajh.25854

Cite this

Short, N. J., Richard-Carpentier, G., Kanagal-Shamanna, R., Patel, K. P., Konopleva, M., Papageorgiou, I., Pemmaraju, N., Borthakur, G., Ravandi, F., DiNardo, C. D., Kadia, T. M., Kantarjian, H., Lamba, J. K., & Daver, N. (2020). Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin. American journal of hematology, 95(9), E225-E228. https://doi.org/10.1002/ajh.25854

Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin. / Short, Nicholas J.; Richard-Carpentier, Guillaume; Kanagal-Shamanna, Rashmi et al.
In: American journal of hematology, Vol. 95, No. 9, 01.09.2020, p. E225-E228.

Research output: Contribution to journal › Letter › peer-review

Short, NJ, Richard-Carpentier, G, Kanagal-Shamanna, R , Patel, KP, Konopleva, M, Papageorgiou, I, Pemmaraju, N , Borthakur, G , Ravandi, F , DiNardo, CD , Kadia, TM , Kantarjian, H, Lamba, JK & Daver, N 2020, 'Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin', American journal of hematology, vol. 95, no. 9, pp. E225-E228. https://doi.org/10.1002/ajh.25854

@article{eb32e79a14124b2784f01814f3accf0a,

title = "Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin",

author = "Short, {Nicholas J.} and Guillaume Richard-Carpentier and Rashmi Kanagal-Shamanna and Patel, {Keyur P.} and Marina Konopleva and Ioannis Papageorgiou and Naveen Pemmaraju and Gautam Borthakur and Farhad Ravandi and DiNardo, {Courtney D.} and Kadia, {Tapan M.} and Hagop Kantarjian and Lamba, {Jatinder K.} and Naval Daver",

note = "Funding Information: American Society of Hematology Junior Faculty Scholar Award in Clinical Research; Charif Souki Fund; Dick Clark Immunotherapy Research Fund; K12 Paul Calabresi Clinical Oncology Scholar Award; Leukemia Lymphoma Society, Translational Program Award; MD Anderson Cancer Center Support Grant, Grant/Award Number: CA016672 Funding information Funding Information: Supported by the MD Anderson Cancer Center Support Grant CA016672, the Charif Souki Fund, and the Dick Clark Immunotherapy Research Fund. N.J.S. is supported by the K12 Paul Calabresi Clinical Oncology Scholar Award and the American Society of Hematology Junior Faculty Scholar Award in Clinical Research. Jatinder Lamba is supported by the Leukemia Lymphoma Society, Translational Program Award.",

year = "2020",

month = sep,

day = "1",

doi = "10.1002/ajh.25854",

language = "English (US)",

volume = "95",

pages = "E225--E228",

journal = "American journal of hematology",

issn = "0361-8609",

publisher = "Wiley-Liss Inc.",

number = "9",

}

TY - JOUR

T1 - Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin

AU - Short, Nicholas J.

AU - Richard-Carpentier, Guillaume

AU - Kanagal-Shamanna, Rashmi

AU - Patel, Keyur P.

AU - Konopleva, Marina

AU - Papageorgiou, Ioannis

AU - Pemmaraju, Naveen

AU - Borthakur, Gautam

AU - Ravandi, Farhad

AU - DiNardo, Courtney D.

AU - Kadia, Tapan M.

AU - Kantarjian, Hagop

AU - Lamba, Jatinder K.

AU - Daver, Naval

N1 - Funding Information: American Society of Hematology Junior Faculty Scholar Award in Clinical Research; Charif Souki Fund; Dick Clark Immunotherapy Research Fund; K12 Paul Calabresi Clinical Oncology Scholar Award; Leukemia Lymphoma Society, Translational Program Award; MD Anderson Cancer Center Support Grant, Grant/Award Number: CA016672 Funding information Funding Information: Supported by the MD Anderson Cancer Center Support Grant CA016672, the Charif Souki Fund, and the Dick Clark Immunotherapy Research Fund. N.J.S. is supported by the K12 Paul Calabresi Clinical Oncology Scholar Award and the American Society of Hematology Junior Faculty Scholar Award in Clinical Research. Jatinder Lamba is supported by the Leukemia Lymphoma Society, Translational Program Award.

PY - 2020/9/1

Y1 - 2020/9/1

UR - http://www.scopus.com/inward/record.url?scp=85085627476&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85085627476&partnerID=8YFLogxK

U2 - 10.1002/ajh.25854

DO - 10.1002/ajh.25854

M3 - Letter

C2 - 32356320

AN - SCOPUS:85085627476

SN - 0361-8609

VL - 95

SP - E225-E228

JO - American journal of hematology

JF - American journal of hematology

IS - 9

ER -

Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this